Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Elevai Labs, Inc. - Common Stock
(NQ:
ELAB
)
0.0830
-0.0093 (-10.08%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Elevai Labs, Inc. - Common Stock
7 Penny Stocks to Watch Now: ELAB, RJDG, BTTC, ATCH, CBDW, and More!
September 25, 2024
Via
AB Newswire
Elevai Labs Inc. Announces Pricing of $8.0 Million Public Offering
September 23, 2024
From
Elevai Labs Inc.
Via
GlobeNewswire
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Results for E-Series Exosome Technology in Potential Melasma Applications
September 10, 2024
From
Elevai Labs Inc.
Via
GlobeNewswire
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Encouraging Data Results Indicating Potential for Hair Restoration Using Proprietary Exosome Technology
September 03, 2024
From
Elevai Labs Inc.
Via
GlobeNewswire
Elevai Labs Inc. Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology Utilizing YuvaBioⓇ Y100™ Mitochondrial Innovation and Elevai Exosomes™
August 28, 2024
From
Elevai Labs Inc.
Via
GlobeNewswire
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai Enfinity™ Topical Exosome Serum
August 26, 2024
From
Elevai Labs Inc.
Via
GlobeNewswire
Elevai Labs Inc. Subsidiary, Elevai Research Inc., Announces Preliminary Positive Research Data Highlighting the Potential of Proprietary Exosome Technology for Skin Health Applications
August 19, 2024
From
Elevai Labs Inc.
Via
GlobeNewswire
Elevai Labs Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
August 14, 2024
From
Elevai Labs Inc.
Via
GlobeNewswire
Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD
July 30, 2024
From
Elevai Labs Inc.
Via
GlobeNewswire
Elevai Labs Inc. Subsidiary, Elevai Skincare, Announces The Elevai S-Series Hair and Scalp Care Product Line
June 28, 2024
From
Elevai Labs Inc.
Via
GlobeNewswire
Elevai Labs Inc. Subsidiary, Elevai Skincare to Debut Upcoming New Product Line at The Aesthetic Show 2024
June 26, 2024
From
Elevai Labs Inc.
Via
GlobeNewswire
Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs
June 14, 2024
From
Elevai Labs Inc.
Via
GlobeNewswire
Elevai Labs Subsidiary, Elevai Skincare, to Present at the Beauty Through Science Conference in Stockholm
May 29, 2024
From
Elevai Labs Inc.
Via
GlobeNewswire
Elevai Labs Inc Subsidiary, Elevai Biosciences, to Present at the UCLA LA-BEST 2024 Conference
May 22, 2024
From
Elevai Labs Inc.
Via
GlobeNewswire
Elevai Labs Inc. Reports First Quarter 2024 Financial Results
May 15, 2024
From
Elevai Labs Inc.
Via
GlobeNewswire
Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity
May 02, 2024
From
Elevai Labs Inc.
Via
GlobeNewswire
Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare
May 01, 2024
From
Elevai Labs Inc.
Via
GlobeNewswire
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
May 01, 2024
From
Elevai Labs Inc.
Via
GlobeNewswire
Elevai Labs Highlights Global Distribution Partnership Overview: Contracts May Secure $4.9M Top Line Revenue Commitments
April 29, 2024
From
Elevai Labs Inc.
Via
GlobeNewswire
ELEVAI Labs Enters the Taiwan Market with Signing of 5th International Distribution Agreement in 14 Months
April 22, 2024
From
Elevai Labs Inc.
Via
GlobeNewswire
Elevai Labs Inc. Reports Record Full Year 2023 and Fourth Quarter Financial Results
March 29, 2024
From
Elevai Labs Inc.
Via
GlobeNewswire
Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market
March 18, 2024
ELEVAI Physician-Dispensed Skincare Now Available Direct to Consumers
From
Elevai Labs Inc.
Via
GlobeNewswire
ELEVAI Labs Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office
January 24, 2024
Utility Patent Covers the formulation for ELEVAI’s flagship exosome-based skin care products
From
Elevai Labs Inc.
Via
GlobeNewswire
ELEVAI LABS, Inc. Reports Strong Preliminary Unaudited Financial Performance for Fiscal Year 2023, Highlighting Significant Revenue Growth and Expanding Global Reach
January 17, 2024
From
Elevai Labs Inc.
Via
GlobeNewswire
ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology
January 16, 2024
ELEVAI Labs to commercialize use of proprietary technology designed to produce high-quality, cGMP grade mesenchymal stromal cells at lower-cost
From
Elevai Labs Inc.
Via
GlobeNewswire
ELEVAI LABS, Inc. to Participate in Upcoming Aesthetic Industry Conferences
January 02, 2024
From
Elevai Labs Inc.
Via
GlobeNewswire
Elevai Labs Inc Announces Financial Results for the Quarter Ended September 30, 2023
December 11, 2023
Company Records Record Quarterly Revenues
From
Elevai Labs Inc.
Via
GlobeNewswire
ELEVAI Labs, Inc. Expands International Distribution into Europe
December 07, 2023
From
Elevai Labs Inc.
Via
GlobeNewswire
Elevai Labs Enters into Licensing Agreement with Yuva Biosciences to Combine Exosome and Mitochondrial Technologies to Develop New Aesthetics Products
November 29, 2023
From
Elevai Labs Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.